Collectively, the top eight blockbuster drugs of 2024 generated over $116 billion in sales last year. Looking closer at these ...

Moderna Inc. recorded a quarterly loss as vaccine sales waned and the company had an unexpected charge for a canceled ...

It marks another quarter of growing pains for the company, which is racing to launch new products and recover from the ...

This update provides insights into critical global health developments, including Merck's halt on Gardasil shipments to China ...

Orders for Merck & Co's oral antiviral for COVID-19 helped to swell the ... but even without the drug sales would have risen 19% thanks to a strong performance from cancer immunotherapy Keytruda ...

Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 ...

Eliquis, a blood thinner marketed in partnership with Bristol Myers Squibb, is Pfizer's largest revenue stream at the moment. It could begin competing with generic versions in the U.S. market in 2028, ...

alleging that their COVID-19 vaccine, Comirnaty, infringed on Moderna's patents. Despite holding exclusive rights to the World's most financially successful drug - KEYTRUDA - Merck shares trade at ...

To illustrate that point, let's discuss two stocks in the biotech industry that have moved in opposite directions so far this ...

Nine of 24 people with measles in Texas are hospitalized for a disease that was considered eliminated in 2000. Kennedy has ...

As Moderna maps out a more cautious future amid lower-than-expected sales of its current products, the company is bolstering ...

After a period of unsteady sales for its key COVID-19 products, Pfizer now sees COVID-related revenue volatility as “largely in the past.”  | The company benefited from higher-than-expected sales of ...